Neptune Technologies & Bioressources-Ord  

(Public, NASDAQ:NEPT)   Watch this stock  
Find more results for NEPT
1.01
-0.01 (-0.98%)
After Hours: 1.17 +0.16 (15.84%)
Feb 12, 4:59PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.99 - 1.08
52 week 0.94 - 1.94
Open 1.01
Vol / Avg. 46,558.00/178,417.00
Mkt cap 79.50M
P/E     -
Div/yield     -
EPS -0.18
Shares 77.94M
Beta 1.28
Inst. own     -
Jan 13, 2016
Q3 2016 Neptune Technologies & Bioressources Inc Earnings Call
Jan 12, 2016
Q3 2016 Neptune Technologies & Bioressources Inc Earnings Release
Jan 8, 2016
Neptune Technologies & Bioressources Inc Acquires Biodroga Inc.
Dec 7, 2015
Preliminary Q3 2016 Neptune Technologies & Bioressources Inc Earnings Release
More events from DailyFinance »    

Address

545 Prom du Centropolis Suite 100
LAVAL, QC H7T 0A3
Canada
+1-450-6872262 (Phone)
+1-450-6872272 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Neptune Technologies & Bioressources Inc is a Canada-based biotechnology company. The Company is engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids (PUFAs). The Company has three operating segments: Neptune, Acasti Pharma Inc. and NeuroBioPharm Inc. The Company's Neptune segment produces and commercializes nutraceutical products. The Company's Acasti Pharma Inc. segment develops and commercializes medical food and pharmaceutical products for cardiovascular diseases. The Company's NeuroBioPharm Inc. segment develops medical food and pharmaceutical products for neurological diseases. The Company's lead product, Neptune Krill Oil (NKO), come in capsule form and serve as a dietary supplement to consumers. The Company's other nutraceutical products include Ecokrill Oil (EKO), Rimfrost Oil, Neptune Krill Aquatein ( NKA) and New Formulation Derived from NKO, which include NKO Beat, NKO Flex and NKO Focus.

Officers and directors

Pierre Fitzgibbon Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
James Stuart Hamilton President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Mario Paradis Chief Financial Officer
Bio & Compensation  - Reuters
Michel Timperio Senior Vice President of Sales - Global Sales
Bio & Compensation  - Reuters
Pierre Lemieux Ph.D. Chief Operating Officer of Acasti
Bio & Compensation  - Reuters
Jean-Daniel Belanger Corporate Secretary and Director - Corporate Affairs
Bio & Compensation  - Reuters
Harlan W. Waksal M.D. Director
Age: 61
Bio & Compensation  - Reuters
Valier Boivin Independent Director
Bio & Compensation  - Reuters
Ronald Denis Independent Director
Bio & Compensation  - Reuters
Adrian Taylor Montgomery Independent Director
Bio & Compensation  - Reuters